Who are Sitafloxacin (S)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): β-lactams or ciprofloxacin, Gatifloxacin 0.3%, Moxifloxacin 0.5% ophthalmic solution, Intracameral Moxifloxacin 0.1%, Vigamox Eye Drops, Moxifloxacin (Topical).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sitafloxacin-s.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Sitafloxacin (S) — Competitive Intelligence Brief

Sitafloxacin (S) (Sitafloxacin (S)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone antibiotic. Area: Infectious diseases.

phase 3 fluoroquinolone antibiotic DNA gyrase and topoisomerase IV Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Sitafloxacin (S) (Sitafloxacin (S)) — Shenzhen Third People's Hospital. Sitafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sitafloxacin (S) TARGET	Sitafloxacin (S)	Shenzhen Third People's Hospital	phase 3	fluoroquinolone antibiotic	DNA gyrase and topoisomerase IV
β-lactams or ciprofloxacin	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluoroquinolone antibiotic class)

Allergan · 1 drug in this class
Shenzhen Third People's Hospital · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
University of Rochester · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sitafloxacin (S) — Competitive Intelligence Brief. https://druglandscape.com/ci/sitafloxacin-s. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab